Response to Comment on Foss-Freitas Et Al. Efficacy and Safety of Glucagon-Like Peptide 1 Agonists in a Retrospective Study of Patients With Familial Partial Lipodystrophy. Diabetes Care 2024;47:653-659
Overview
Overview
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Zolotov S, Xing C, Mahamid R, Shalata A, Sheikh-Ahmad M, Garg A
. Homozygous LIPE mutation in siblings with multiple symmetric lipomatosis, partial lipodystrophy, and myopathy. Am J Med Genet A. 2016; 173(1):190-194.
PMC: 5788284.
DOI: 10.1002/ajmg.a.37880.
View
2.
Sollier C, Capel E, Aguilhon C, Smirnov V, Auclair M, Douillard C
. LIPE-related lipodystrophic syndrome: clinical features and disease modeling using adipose stem cells. Eur J Endocrinol. 2020; 184(1):155-168.
DOI: 10.1530/EJE-20-1013.
View
3.
Foss-Freitas M, Imam S, Neidert A, Gomes A, Broome D, Oral E
. Efficacy and Safety of Glucagon-Like Peptide 1 Agonists in a Retrospective Study of Patients With Familial Partial Lipodystrophy. Diabetes Care. 2024; 47(4):653-659.
PMC: 10973902.
DOI: 10.2337/dc23-1614.
View
4.
Zhou Y, Zhang L, Ding Y, Zhai Y
. Case report: First Chinese patient with family partial lipodystrophy type 6 due to novel compound heterozygous mutations in the LIPE gene. Front Genet. 2024; 15:1417613.
PMC: 11303181.
DOI: 10.3389/fgene.2024.1417613.
View